AR and prostate cancer: In the present study, we demonstrated that the orphan nuclear receptor TLX, which displayed an upregulation expression in both clinical mCRPC and xenograft models, could confer androgen insensitivity in AR-positive prostate cancer cells in vitro and in vivo.